Laurent Pharmaceuticals featured in Biotech Finances
MONTREAL, QC, Canada – July 18, 2016 th, 2015
Laurent Pharmaceuticals featured in Biotech Finances.
NEWS
Laurent Pharmaceuticals to receive investment from Cystic Fibrosis Canada
MONTREAL, QC, Canada – March 17th, 2016
Laurent Pharmaceuticals Inc. announced today the closing of a financing round led by Cystic Fibrosis Canada. Existing investors Aligo Innovation LP (previously MSBi Valorisation) and members of Anges Quebec, as well as other existing and new private investors, also participated in the round.
This investment will allow the preparation of the upcoming Phase 2 clinical trial with LAU-7b in cystic fibrosis (CF) patients, planned to start later this year in Canada and United States. LAU-7b is a once-a-day oral drug addressing the persistent and unresolved inflammation, a leading cause of lung tissue destruction in CF.
“We are pleased to support Laurent Pharmaceuticals in its effort to bring this therapy closer to CF patients”, said Norma Beauchamp, the CEO of Cystic Fibrosis Canada. “This is Cystic Fibrosis Canada’s first direct investment in a company and it builds on our mission to end CF by encouraging Canadian start-ups companies to advance disruptive technologies for our patient community. We are impressed by LAU-7b’s potential benefits and by the company’s efforts in bringing this therapy to the next level of development.”
Laurent Pharmaceuticals announces positive Phase 1b topline results for LAU-7b in Cystic Fibrosis
- LAU-7b is safe and well tolerated by adult Cystic Fibrosis (CF) patients
- The pharmacokinetic profile fully achieved the protocol dose selection rationale
- Study drug shows a convergence of multiple promising pharmacodynamic trends
MONTREAL, QC, Canada - June 15th, 2015
Laurent Pharmaceuticals Inc. announced today positive topline results from a Phase 1b clinical trial with LAU-7b in adult CF patients. LAU-7b is a novel oral formulation of fenretinide, a synthetic retinoid investigated for its lipid modulating properties and potential to address the aberrant inflammatory response in CF. The study was conducted at the McGill University Health Centre (MUHC). The trial demonstrated that LAU-7b administrated orally in ascending doses up to 300mg, during three cycles of 21 consecutive days, was safe and well tolerated by adult CF patients. The pharmacokinetic profile of LAU-7 fully achieved the targeted blood levels and dose selection rationale. The treatment also normalized the lipid imbalance and decreased oxidative stress in a vast majority of patients, causing a shift towards an anti-inflammatory pattern particularly at the highest dose tested.
Laurent Pharmaceuticals featured in BioCentury Magazine
MONTREAL, QC, Canada – September 15 th, 2015
Laurent Pharmaceuticals Inc. announced today that the LAU-7b program addressing aberrant inflammation is featured in the September 14th issue of BioCentury, one of the most widely read publications in the pharma industry.
Published under the title “Balancing Act”, the article describes how Laurent Pharmaceuticals thinks its LAU-7b can carve out a niche in CF by correcting the inflammatory imbalance in CF patients and reduce lung deterioration over time, when given on top of standard of care.